I

t’s been lauded as an essential public health tool and maligned as “a party drug.” And now it’s on its way to going generic.

The Food and Drug Administration on Thursday approved Teva’s bid to market the first generic form of the daily HIV prevention pill sold as Truvada by Gilead. When it becomes available, it will be closely watched for whether it can meaningfully drive down prices and widen access — which may fuel the debate over the role the medication should play in combating HIV.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.